Key result
Drug-eluting stents resulted in a similar rate of major adverse cardiac events at 2 years compared to bare-metal stents in patients with STEMI.
Why the study?
The study was conducted to compare the effectiveness and safety of drug eluting stents with bare metal stents in patients presenting with STEMI in a real-world setting.
Does the use of drug-eluting stents compared to bare-metal stents improve clinical outcomes in patients presenting with STEMI undergoing primary PCI?
Cohort (n=1,596)
No
Does the use of drug-eluting stents compared to bare-metal stents improve clinical outcomes in patients presenting with STEMI undergoing primary PCI?
In a real-world STEMI cohort, DES implantation was associated with higher 1-year MACE and stent thrombosis compared to BMS, but these differences vanished by 2 years, suggesting non-inferiority in the longer term despite early risks in this specific population.
Answers are grounded in this paper and cite their sources.
Similar 2-year MACE with DES versus BMS in STEMI leaves open early safety signals and stent selection in primary PCI.
Background: The aim of this study was to compare the effectiveness and safety of drug eluting stents (DES) with bare metal stents (BMS) in patients presented with ST- segment elevation myocardial infarction (STEMI) in a real world setting. Methods: One thousand five hundred ninety six STEMI patients treated with primary percutaneous coronary intervention from January 2013 to March 2016 were enrolled to study. One thousand one hundred ninety four of them received BMS while 402 of them received DES. Patients were analyzed for major adverse cardiac events (MACE) and stent thrombosis (ST). Results: There was no difference at 30 days in relation of MACE, all cause death, re-MI, TVR, TLR and ST. The cumulative incidence of MACE was significantly higher in DES group (9,2% vs. 7,0%, p = 0.02) at 1 year. Stent thrombosis and re-MI incidence were significantly higher in DES group (4,2% vs. 2,6%, p = 0.028, 6,9% vs. 4,8%, p = 0.015) respectively at 1 year. There was no statistically significant difference in relation of all cause death, TVR and TLR at 1 year. The statistically differences between groups vanished at 2 year and the groups looked similar. Male gender (HR, 1.40; 95% CI, 1.00 to 1.94; p = 0.043) and presence of DM (HR, 1.73; 95% CI, 1.29 to 2.32; p<0,001) were found to be independent predictors of 2-year MACE. Conclusion: Our study showed effectiveness and safety of DES in STEMI. Despite increased incidence of MACE, re-MI and ST in 1-year, DES was found to be non-inferior to BMS at 2-year follow up.
No takes yet. Share an insight, caveat, or question.
Kaya et al. (2019) conducted a cohort in ST-Segment Elevation Myocardial Infarction (STEMI) (n=1,596). Drug-eluting stents vs. Bare-metal stents was evaluated on Major adverse cardiac events (MACE) at 2 years (p=0.062). Drug-eluting stents resulted in a similar rate of major adverse cardiac events at 2 years compared to bare-metal stents in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: